In July 2020, researchers from the University of Nebraska and the Texas Biomedical Research Institute are recommending more research into how CBD derived from cannabis, might help treat the dangerous lung inflammation from the coronavirus (sars-covid-2).
Cannabinoid-based pharmaceutical products is an emerging field in the clinical practice in many countries. The regulatory changes around the world in recent years makes it possible to create a larger knowledge base and understanding of cannabinoids and their influence on the human physiology. However, this is still questioned by a majority of physicians as they demand more science and education in order to handle cannabis in the clinical setting.
Even though many clinical trials are needed in order to understand the full potential of cannabinoids, the literature illustrate that we know more about cannabis than we know about many other drugs. The latter includes approved pharmaceutical drugs on the market.
The book can be read from start to end, but also used as reference guide book. In this regard, it is recommended that the first four sections be read first.